VIDEO: No ‘hard-to-reach’ patients in HCV, just ‘hardly reached’

In this exclusive video, Joss O’Loan, MBBS, from the Hepatitis C Kombi Clinic in Brisbane, Australia, discusses two studies presented at The Digital International Liver Congress on HCV elimination programs using Epclusa.The first study looked at the efficacy of the Epclusa (sofosbuvir/velpatasvir, Gilead Sciences) in an Australian primary care setting. Researchers found that general practitioner- and nurse-led clinics could offer care with high sustained virologic response rates.The second study also showed that the treatment could provide high cure rates, this time among underservedRead More

Share on facebook
Share on twitter
Share on linkedin